Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-31 - Denosumab

The participating funds aim to conclude discount contracts pursuant to Section 130a (8) SGB V with all suitable pharmaceutical companies for the active substance Denosumab. The procedure is divided into two lots for the named active substance. For details, see the information for the respective lot. The contract is concluded within the framework of the Open-House-Biologika procedure of the participating funds: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurers do not guarantee exclusivity to individual contracting partners. The contract period is a maximum of 24 months, commencing on 01.12.2025. The contract ends at the latest on 30.11.2027, regardless of the date of the contract conclusion. Joining this Open-House procedure is possible at any time during the contract period. The information provided on the binding period is not relevant in this case and is solely due to the mandatory requirements of the form. All further information can be found in the participation and contract documents.